Indications and results for splenectomy for beta thalassemia in two hundred and twenty-one pediatric patients.
To determine the advantages and complications of splenectomy in the treatment of beta thalassemia, 221 splenectomies for thalassemia performed upon pediatric patients from 1971 to 1982 are evaluated. There were 125 boys and 96 girls with a mean age of 8.2 +/- 2.5 years at the time of the operation. Sixty-one other patients who underwent splenectomy for other diseases served as the controls. Early and late complications after splenectomy are considered with a follow-up study of ten years. Hemoglobin (Hb) value, transfusional quotients and mean of transfused blood previous to surgical treatment are matched with the same parameters evaluated during the follow-up period. The effect of treatment with salicylates and dipyridamole upon the incidence of early complications after operation is analyzed. The postoperative complications in patients with thalassemia were 43.4 versus 3.2 per cent (p less than 0.01) registered in control patients. Late complications occurred with an incidence of 10.7 per cent and were due principally to sepsis. Six patients died of sepsis during the follow-up period, but the mortality rate for sepsis in the patients we studied was significantly lower than that reported by others in 73 instances of splenectomy for beta thalassemia. Blood consumption dropped from 270 +/- 99 to 155 +/- 31 milliliters per kilogram per year postoperatively (p less than 0.01) and Hb levels rose from 9.7 +/- 1.3 to 11.2 +/- 0.7 grams per milliliter. These results suggest that, even though splenectomy for beta thalassemia causes a relevant incidence of complications and fatalities, surgical treatment permits an improvement in the quality of the lives of patients with beta thalassemia and significantly reduces blood consumption. Prophylactic antibiotic therapy can reduce the incidence of sepsis, as was observed in the patients we studied.
Pinna
A D
AD
Istituto di Chirurgia, University of Cagliari, Italy.
Argiolu
F
F
Marongiu
L
L
Pinna
D C
DC
D001241:Aspirin / Q000627:therapeutic use; D001803:Blood Transfusion; D002561:Cerebrovascular Disorders / Q000517:prevention & control; D002648:Child; D004176:Dipyridamole / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D007239:Infections / Q000209:etiology; D008297:Male; D011182:Postoperative Care; D011183:Postoperative Complications / Q000517:prevention & control; D013156:Splenectomy / Q000009:adverse effects; D013789:Thalassemia / Q000628:therapy*; D013927:Thrombosis / Q000517:prevention & control
D004176:Dipyridamole; D001241:Aspirin